Alvotech stock slides as FDA issues CRL for AVT05, company cuts EBITDA outlook

14 hours ago 1
Scientist analyze biochemical samples in advanced scientific laboratory. Medical professional use microscope look microbiological developmental of viral. Biotechnology research in science lab.

Alvotech (ALVO) said Monday that the U.S. Food and Drug Administration issued a complete response letter for its biologics license application for AVT05, a proposed biosimilar to Simponi and Simponi Aria, sending the company’s shares 22% lower in

Recommended For You

More Trending News

Read Entire Article
  1. Homepage
  2. Finance
  3. Alvotech stock slides as FDA issues CRL for AVT05, company cuts EBITDA outlook

Related

Fabrinet outlines Q2 revenue target of up to $1.1B while accelerating HPC and DCI growth

Fabrinet outlines Q2 revenue target of up to $1.1B while acc...

12 minutes ago 0
TrueBlue targets 4% to 10% Q4 revenue growth as skilled and energy segments accelerate

TrueBlue targets 4% to 10% Q4 revenue growth as skilled and ...

12 minutes ago 0
CompoSecure outlines $510M 2026 sales target as Husky acquisition drives platform transformation

CompoSecure outlines $510M 2026 sales target as Husky acquis...

22 minutes ago 0
Ameresco reaffirms 2025 guidance and targets 10% revenue, 20% EBITDA growth amid robust data center and energy asset demand

Ameresco reaffirms 2025 guidance and targets 10% revenue, 20...

32 minutes ago 0
Exxon CEO says giant UAE oilfield could hit capacity target earlier than planned

Exxon CEO says giant UAE oilfield could hit capacity target ...

47 minutes ago 0
Medifast outlines Q4 2025 revenue guidance of $65M–$80M amid strategic shift to metabolic health solutions

Medifast outlines Q4 2025 revenue guidance of $65M–$80M amid...

1 hour ago 0
Kosmos targets Jubilee production of 70,000 barrels per day by year-end while reducing CapEx below $350M

Kosmos targets Jubilee production of 70,000 barrels per day ...

1 hour ago 0
Gaia outlines low double-digit revenue growth and expands AI integration while advancing Igniton rollout

Gaia outlines low double-digit revenue growth and expands AI...

1 hour ago 0
B2Gold says Fekola complex in Mali maintains full operational capacity

B2Gold says Fekola complex in Mali maintains full operationa...

1 hour ago 0
Vertex falls despite Q3 double beats as 2025 revenue guidance narrowed

Vertex falls despite Q3 double beats as 2025 revenue guidanc...

1 hour ago 0
Grab reports Q3 results

Grab reports Q3 results

1 hour ago 0
Global X Short-Term Treasury Ladder ETF declares $0.155 dividend

Global X Short-Term Treasury Ladder ETF declares $0.155 divi...

1 hour ago 0
Global X Long-Term Treasury Ladder ETF declares $0.168 dividend

Global X Long-Term Treasury Ladder ETF declares $0.168 divid...

1 hour ago 0
Here are the major earnings before the open Tuesday

Here are the major earnings before the open Tuesday

1 hour ago 0
Global X U.S. Preferred ETF declares $0.10 dividend

Global X U.S. Preferred ETF declares $0.10 dividend

1 hour ago 0
Global X Variable Rate Preferred ETF declares $0.1375 dividend

Global X Variable Rate Preferred ETF declares $0.1375 divide...

1 hour ago 0
PGIM AAA CLO ETF declares $0.2208 dividend

PGIM AAA CLO ETF declares $0.2208 dividend

1 hour ago 0
AltaGas to retain MVP as long-term investment, launches C$400M bought deal financing

AltaGas to retain MVP as long-term investment, launches C$40...

1 hour ago 0
Diversified Royalty declares CAD 0.0229 dividend

Diversified Royalty declares CAD 0.0229 dividend

1 hour ago 0
Petrus Resources declares CAD 0.01 dividend

Petrus Resources declares CAD 0.01 dividend

1 hour ago 0

Trending

Popular

STAG Industrial raises core FFO guidance to $2.52–$2.54 per share as leasing momentum accelerates

STAG Industrial raises core FFO guidance to $2.52–$2.54 per ...

4 days ago 4
Amneal raises 2025 EPS guidance and outlines $300M–$500M CREXONT sales target as portfolio expansion accelerates

Amneal raises 2025 EPS guidance and outlines $300M–$500M CRE...

4 days ago 4
English (US) English (US) ·
About Us · Contact Us · Terms & Conditions ·

© FBT Company 2025. All rights are reserved